RU2015140599A - UREA DERIVATIVES AND THEIR APPLICATION AS PROTEIN INHIBITORS, BINDING FATTY ACIDS - Google Patents

UREA DERIVATIVES AND THEIR APPLICATION AS PROTEIN INHIBITORS, BINDING FATTY ACIDS Download PDF

Info

Publication number
RU2015140599A
RU2015140599A RU2015140599A RU2015140599A RU2015140599A RU 2015140599 A RU2015140599 A RU 2015140599A RU 2015140599 A RU2015140599 A RU 2015140599A RU 2015140599 A RU2015140599 A RU 2015140599A RU 2015140599 A RU2015140599 A RU 2015140599A
Authority
RU
Russia
Prior art keywords
substituted
ureido
cycloalkyl
compound according
alkyl
Prior art date
Application number
RU2015140599A
Other languages
Russian (ru)
Other versions
RU2642454C2 (en
Inventor
Бернд Бюттельманн
Симона М. ЧЕККАРЕЛЛИ
Аурелия КОНТЕ
Хольгер Кюне
Бернд Кун
Вернер НАЙДХАРТ
ЗАНДЕР Ульрике ОБСТ
Ханс РИХТЕР
Original Assignee
Ф. Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф. Хоффманн-Ля Рош Аг filed Critical Ф. Хоффманн-Ля Рош Аг
Publication of RU2015140599A publication Critical patent/RU2015140599A/en
Application granted granted Critical
Publication of RU2642454C2 publication Critical patent/RU2642454C2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C273/00—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C273/18—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas
    • C07C273/1854—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas by reactions not involving the formation of the N-C(O)-N- moiety
    • C07C273/1863—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas by reactions not involving the formation of the N-C(O)-N- moiety from urea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5302—Apparatus specially adapted for immunological test procedures
    • G01N33/5304—Reaction vessels, e.g. agglutination plates

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)

Claims (56)

1. Соединение формулы (I)1. The compound of formula (I)
Figure 00000001
,
Figure 00000001
, где R1 и R2 вместе с атомом углерода, к которому они присоединены, образуют циклоалкил;where R 1 and R 2 together with the carbon atom to which they are attached form cycloalkyl; R3 представляет собой Н, алкил или циклоалкил;R 3 represents H, alkyl or cycloalkyl; R4 представляет собой Н, алкил или циклоалкил;R 4 represents H, alkyl or cycloalkyl; W представляет собой связь, -О-, -S-, -NR5 -, -С(О)-, -S(O)2-, -С(О)-NR5- или -CR6R7-,W represents a bond, —O—, —S—, —NR 5 -, —C (O) -, —S (O) 2 -, —C (O) —NR 5 -, or —CR 6 R 7 -, R5 представляет собой Н, алкил или циклоалкил;R 5 represents H, alkyl or cycloalkyl; R6 и R7 независимо выбраны из Н, алкила или циклоалкила;R 6 and R 7 are independently selected from H, alkyl or cycloalkyl; А представляет собой замещенный фенил, замещенный тиофенил, замещенный бензотиофенил, замещенный тиенопиридинил, где замещенный фенил, замещенный тиофенил, замещенный бензотиофенил и замещенный тиенопиридинил замещены R8, R9 и R10;A is substituted phenyl, substituted thiophenyl, substituted benzothiophenyl, substituted thienopyridinyl, wherein substituted phenyl, substituted thiophenyl, substituted benzothiophenyl and substituted thienopyridinyl are substituted with R 8 , R 9 and R 10 ; В представляет собой замещенный циклоалкил, замещенный циклоалкенил, замещенный пиридинил, замещенный фенил, замещенный тиофенил, замещенный бензотиофенил, замещенный тиенопиридинил, где замещенный циклоалкил, замещенный циклоалкенил, замещенный пиридинил, замещенный фенил, замещенный тиофенил, замещенный бензотиофенил и замещенный тиенопиридинил замещены R11, R12 и R13;B represents a substituted cycloalkyl, substituted cycloalkenyl, substituted pyridinyl, substituted phenyl, substituted thiophenyl, substituted benzothiophenyl, substituted thienopyridines, wherein substituted cycloalkyl, substituted cycloalkenyl, substituted pyridinyl, substituted phenyl, substituted thiophenyl, optionally substituted benzothiophenyl, and substituted thienopyridine substituted by R 11, R 12 and R 13 ; R8, R9, R10 независимо выбраны из Н, алкила, алкенила, алкинила, гидроксиалкила, галогеналкила, гидроксигалогеналкила, циклоалкила, циклоалкенила, циклоалкилалкила, циклоалкенилалкила, циклоалкилалкокси, циклоалкокси, циклоалкоксиалкила, циклоалкилалкоксиалкила, алкокси, алкоксиалкила, галогеналкокси,R 8 , R 9 , R 10 are independently selected from H, alkyl, alkenyl, alkynyl, hydroxyalkyl, haloalkyl, hydroxyhaloalkyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkenylalkyl, cycloalkylalkoxy, cycloalkoxy, cycloalkoxyalkylalkyl, cycloalkoxyalkylalkyl, галогеналкоксиалкила, алкоксиалкокси, алкоксиалкоксиалкила, фенила, замещенного фенила, пиридинила, замещенного пиридинила, галогена, гидрокси, циано, замещенного аминосульфонила, замещенного аминокарбонила, замещенного амино и замещенного аминоалкила, где замещенный аминосульфонил, замещенный аминокарбонил, замещенный амино и замещенный аминоалкил замещены на атоме азота одним или двумя заместителями, независимо выбранными из водорода, алкила, циклоалкила, циклоалкилалкила, гидроксиалкила, алкоксиалкила, алкилкарбонила и циклоалкилкарбонила, и где замещенный фенил и замещенный пиридинил замещены одним-тремя заместителями, выбранными из алкила, гидроксиалкила, галогеналкила, циклоалкила, алкокси, галогеналкокси, галогена, гидрокси и циано;haloalkoxyalkyl, alkoxyalkoxy, alkoxyalkoxyalkyl, phenyl, substituted phenyl, pyridinyl, substituted pyridinyl, halogen, hydroxy, cyano, substituted amino sulfonyl, substituted aminocarbonyl, substituted amino and substituted aminoalkyl, where substituted amino-sulfonyl substituted amino one or two substituents independently selected from hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, hydroxyalkyl, alkoxyalkyl, alkylcarbonyl and cycloalk alkylcarbonyl, and wherein substituted phenyl and substituted pyridinyl are substituted with one to three substituents selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, alkoxy, haloalkoxy, halogen, hydroxy and cyano; R11, R12 и R13 независимо выбраны из Н, алкила, алкенила, алкинила, гидроксиалкила, галогеналкила, гидроксигалогеналкила, циклоалкила, циклоалкенила, циклоалкилалкила, циклоалкенилалкила, циклоалкилалкокси, циклоалкокси, циклоалкоксиалкила, циклоалкилалкоксиалкила, алкокси, алкоксиалкила, галогеналкокси, галогеналкоксиалкила, алкоксиалкокси, алкоксиалкоксиалкила, фенила, замещенного фенила, пиридинила, замещенного пиридинила, галогена, гидрокси, циано, замещенного аминосульфонила, замещенного аминокарбонила, замещенного амино и замещенного аминоалкила, где замещенный аминосульфонил, замещенный аминокарбонил, замещенный амино и замещенный аминоалкил замещены на атоме азота одним или двумя заместителями, независимо выбранными из водорода, алкила, циклоалкила, циклоалкилалкила, гидроксиалкила, алкоксиалкила, алкилкарбонила и циклоалкилкарбонила, и где замещенный фенил и замещенный пиридинил замещены одним-тремя заместителями, выбранными из алкила, гидроксиалкила, галогеналкила, циклоалкила, алкокси, галогеналкокси, галогена, гидрокси и циано;R 11 , R 12 and R 13 are independently selected from H, alkyl, alkenyl, alkynyl, hydroxyalkyl, haloalkyl, hydroxyhaloalkyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkenylalkyl, cycloalkylalkoxyalkylalkyl, cycloalkoxyalkoxyalkylalkyl, cycloalkoxyalkylalkyl , alkoxyalkoxyalkyl, phenyl, substituted phenyl, pyridinyl, substituted pyridinyl, halogen, hydroxy, cyano, substituted aminosulfonyl, substituted aminocarbonyl, substituted amino and substituted amino alkyl, where substituted amino-sulfonyl, substituted amino-carbonyl, substituted amino and substituted amino-alkyl are substituted on the nitrogen atom with one or two substituents independently selected from hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, hydroxyalkyl, alkoxyalkyl, alkylcarbonyl and cycloalkyl-phenyl, and substituted substituted with one to three substituents selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, alkoxy, haloalkoxy, halogen, hydroxy and cyano; или их фармацевтически приемлемые соли.or their pharmaceutically acceptable salts. 2. Соединение по п. 1, в котором R1 и R2 вместе с атомом углерода, к которому они присоединены, образуют циклопропил, циклобутил или циклопентил.2. The compound of claim 1, wherein R 1 and R 2, together with the carbon atom to which they are attached, form cyclopropyl, cyclobutyl or cyclopentyl. 3. Соединение по п. 1, в котором R1 и R2 вместе с атомом углерода, к которому они присоединены, образуют циклопропил или циклопентил.3. The compound of claim 1, wherein R 1 and R 2, together with the carbon atom to which they are attached, form cyclopropyl or cyclopentyl. 4. Соединение по п. 1, в котором R3 представляет собой Н или алкил.4. The compound of claim 1, wherein R 3 is H or alkyl. 5. Соединение по п. 1, в котором R3 представляет собой Н.5. The compound according to claim 1, in which R 3 represents N. 6. Соединение по п. 1, в котором R4 представляет собой Н.6. The compound according to claim 1, in which R 4 represents N. 7. Соединение по п. 1, в котором W представляет собой связь.7. The compound of claim 1, wherein W is a bond. 8. Соединение по п. 1, в котором A представляет собой фенил, замещенный R8, R9 и R10.8. The compound of claim 1, wherein A is phenyl substituted with R 8 , R 9 and R 10 . 9. Соединение по п.1, в котором A представляет собой фенил, трифторметилфенил, хлорфенил, дихлорфенил или хлорфторфенил.9. The compound according to claim 1, in which A represents phenyl, trifluoromethylphenyl, chlorophenyl, dichlorophenyl or chlorofluorophenyl. 10. Соединение по п.1, в котором A представляет собой хлорфенил или хлорфторфенил.10. The compound according to claim 1, in which A represents chlorophenyl or chlorofluorophenyl. 11. Соединение по п.1, в котором B представляет собой фенил, замещенный R11, R12 и R13.11. The compound according to claim 1, in which B is phenyl substituted with R 11 , R 12 and R 13 . 12. Соединение по п.1, в котором B представляет собой фенил или фторфенил.12. The compound according to claim 1, in which B represents phenyl or fluorophenyl. 13. Соединение по п.1, в котором R8, R9 и R10 независимо выбраны из Н, галогеналкила и галогена.13. The compound according to claim 1, in which R 8 , R 9 and R 10 are independently selected from H, haloalkyl and halogen. 14. Соединение по п.1, в котором R8, R9 и R10 независимо выбраны из Н и галогена.14. The compound according to claim 1, in which R 8 , R 9 and R 10 are independently selected from H and halogen. 15. Соединение по п.1, в котором R11, R12 и R13 независимо выбраны из Н и галогена.15. The compound according to claim 1, in which R 11 , R 12 and R 13 are independently selected from H and halogen. 16. Соединение по п.1, выбранное из16. The compound according to claim 1, selected from 1-(3-(бифенил-2-ил)-1-метилуреидо)циклопропанкарбоновой кислоты;1- (3- (biphenyl-2-yl) -1-methylureido) cyclopropanecarboxylic acid; 1-(3-(4-хлорбифенил-2-ил)уреидо)циклопентанкарбоновой кислоты;1- (3- (4-chlorobiphenyl-2-yl) ureido) cyclopentanecarboxylic acid; 1-(3-(4-хлорбифенил-2-ил)уреидо)циклопропанкарбоновой кислоты;1- (3- (4-chlorobiphenyl-2-yl) ureido) cyclopropanecarboxylic acid; 1-(3-(4-хлорбифенил-2-ил)уреидо)циклобутанкарбоновой кислоты;1- (3- (4-chlorobiphenyl-2-yl) ureido) cyclobutanecarboxylic acid; 1-(3-(4-хлор-4'-фторбифенил-2-ил)уреидо)циклопропанкарбоновой кислоты;1- (3- (4-chloro-4'-fluorobiphenyl-2-yl) ureido) cyclopropanecarboxylic acid; 1-(3-(4-хлор-4'-фторбифенил-2-ил)уреидо)циклопентанкарбоновой кислоты;1- (3- (4-chloro-4'-fluorobiphenyl-2-yl) ureido) cyclopentanecarboxylic acid; 1-(3-(4-хлор-5-фторбифенил-2-ил)уреидо)циклопропанкарбоновой кислоты;1- (3- (4-chloro-5-fluorobiphenyl-2-yl) ureido) cyclopropanecarboxylic acid; 1-(3-(5-хлорбифенил-2-ил)уреидо)циклопропанкарбоновой кислоты;1- (3- (5-chlorobiphenyl-2-yl) ureido) cyclopropanecarboxylic acid; 1-(3-(4-хлор-5-фторбифенил-2-ил)уреидо)циклопентанкарбоновой кислоты;1- (3- (4-chloro-5-fluorobiphenyl-2-yl) ureido) cyclopentanecarboxylic acid; 1-(3-(4,6-дихлордифенил-2-ил)уреидо)циклопропанкарбоновой кислоты;1- (3- (4,6-dichlorodiphenyl-2-yl) ureido) cyclopropanecarboxylic acid; 1-(3-(4,6-дихлордифенил-2-ил)уреидо)циклопентанкарбоновой кислоты;1- (3- (4,6-dichlorodiphenyl-2-yl) ureido) cyclopentanecarboxylic acid; 1-(3-(4-(трифторметил)бифенил-2-ил)уреидо)циклопентанкарбоновой кислоты;1- (3- (4- (trifluoromethyl) biphenyl-2-yl) ureido) cyclopentanecarboxylic acid; 1-(3-(4-(трифторметил)бифенил-2-ил)уреидо)циклопропанкарбоновой кислоты;1- (3- (4- (trifluoromethyl) biphenyl-2-yl) ureido) cyclopropanecarboxylic acid; 1-(3-(5-хлор-4'-фторбифенил-2-ил)уреидо)циклопентанкарбоновой кислоты;1- (3- (5-chloro-4'-fluorobiphenyl-2-yl) ureido) cyclopentanecarboxylic acid; 1-(3-(5-хлор-4'-фторбифенил-2-ил)уреидо)циклопропанкарбоновой кислоты;1- (3- (5-chloro-4'-fluorobiphenyl-2-yl) ureido) cyclopropanecarboxylic acid; 1-(3-(5-хлорбифенил-2-ил)уреидо)циклопентанкарбоновой кислоты;1- (3- (5-chlorobiphenyl-2-yl) ureido) cyclopentanecarboxylic acid; и их фармацевтически приемлемых солей.and their pharmaceutically acceptable salts. 17. Соединение по п. 1, выбранное из17. The compound according to claim 1, selected from 1-(3-(4-хлор-4'-фторбифенил-2-ил)уреидо)циклопентанкарбоновой кислоты;1- (3- (4-chloro-4'-fluorobiphenyl-2-yl) ureido) cyclopentanecarboxylic acid; 1-(3-(4-хлор-5-фторбифенил-2-ил)уреидо)циклопропанкарбоновой кислоты;1- (3- (4-chloro-5-fluorobiphenyl-2-yl) ureido) cyclopropanecarboxylic acid; и их фармацевтически приемлемых солей.and their pharmaceutically acceptable salts. 18. Соединение по любому из пп. 1-17 для применения в качестве терапевтически активного вещества.18. The compound according to any one of paragraphs. 1-17 for use as a therapeutically active substance. 19. Фармацевтическая композиция, содержащая соединение по любому из пп. 1-17 и терапевтически инертный носитель.19. A pharmaceutical composition comprising a compound according to any one of paragraphs. 1-17 and a therapeutically inert carrier. 20. Применение соединения по любому из пп. 1-17 для лечения или профилактики сахарного диабета 2 типа, атеросклероза, рака, хронической почечной недостаточности и неалкогольного стеатогепатита.20. The use of compounds according to any one of paragraphs. 1-17 for the treatment or prevention of type 2 diabetes mellitus, atherosclerosis, cancer, chronic renal failure, and non-alcoholic steatohepatitis. 21. Соединение по любому из пп. 1-17 для лечения или профилактики сахарного диабета 2 типа, атеросклероза, рака, хронической почечной недостаточности и неалкогольного стеатогепатита.21. The compound according to any one of paragraphs. 1-17 for the treatment or prevention of type 2 diabetes mellitus, atherosclerosis, cancer, chronic renal failure, and non-alcoholic steatohepatitis. 22. Применение соединения по любому из пп. 1-17 для изготовления лекарственного средства для лечения или профилактики диабета 2 типа, атеросклероза, рака, хронической почечной недостаточности и неалкогольного стеатогепатита.22. The use of compounds according to any one of paragraphs. 1-17 for the manufacture of a medicament for the treatment or prevention of type 2 diabetes, atherosclerosis, cancer, chronic renal failure, and non-alcoholic steatohepatitis. 23. Способ лечения или профилактики сахарного диабета 2 типа, атеросклероза, рака, хронической почечной недостаточности и неалкогольного стеатогепатита, который включает введение эффективного количества соединения по любому из пл. 1-17.23. A method of treating or preventing type 2 diabetes mellitus, atherosclerosis, cancer, chronic renal failure, and non-alcoholic steatohepatitis, which comprises administering an effective amount of a compound according to any one of pl. 1-17.
RU2015140599A 2013-03-20 2014-03-17 Urea derivatives and their application as inhibitors of fatty acids connecting protein RU2642454C2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13160088.4 2013-03-20
EP13160088 2013-03-20
PCT/EP2014/055224 WO2014146995A1 (en) 2013-03-20 2014-03-17 Urea derivatives and their use as fatty-acid binding protein (fabp) inhibitors

Publications (2)

Publication Number Publication Date
RU2015140599A true RU2015140599A (en) 2017-04-26
RU2642454C2 RU2642454C2 (en) 2018-01-25

Family

ID=47900931

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015140599A RU2642454C2 (en) 2013-03-20 2014-03-17 Urea derivatives and their application as inhibitors of fatty acids connecting protein

Country Status (13)

Country Link
US (1) US9278918B2 (en)
EP (1) EP2991967A1 (en)
JP (1) JP6235048B2 (en)
KR (1) KR101804650B1 (en)
CN (1) CN105308020B (en)
AR (1) AR095570A1 (en)
BR (1) BR112015024109A2 (en)
CA (1) CA2898534C (en)
HK (1) HK1214238A1 (en)
MX (1) MX2015013365A (en)
RU (1) RU2642454C2 (en)
TW (1) TWI629258B (en)
WO (1) WO2014146995A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10421756B2 (en) 2015-07-06 2019-09-24 Rodin Therapeutics, Inc. Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
HUE057041T2 (en) 2015-07-06 2022-04-28 Alkermes Inc Hetero-halo inhibitors of histone deacetylase
SG10201912107UA (en) 2016-10-06 2020-02-27 Daiichi Sankyo Co Ltd Urea derivative
PL3570834T3 (en) 2017-01-11 2022-05-23 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
RS63343B1 (en) 2017-08-07 2022-07-29 Alkermes Inc Bicyclic inhibitors of histone deacetylase
CN113401281B (en) * 2021-08-17 2021-11-02 南通御美津精密工业有限公司 Closing device for ship body anchor recess outer plate opening
KR20240065110A (en) * 2021-09-15 2024-05-14 셀로람 인코포레이티드 FABP4/5 inhibitors, methods of use and preparation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0091596B1 (en) * 1982-04-08 1991-09-11 Shell Internationale Researchmaatschappij B.V. Hydantoins, their preparation and application
IL135176A0 (en) * 1997-11-10 2001-05-20 Bristol Myers Squibb Co Benzothiazole derivatives and pharmaceutical compositions containing the same
US6727247B2 (en) * 2001-12-10 2004-04-27 Hoffman-La Roche Inc. Substituted benzothiazole amide derivatives
ATE430728T1 (en) * 2002-10-21 2009-05-15 Janssen Pharmaceutica Nv SUBSTITUTED TETRALINES AND INDANES AND THEIR USE
US7202269B2 (en) 2003-10-30 2007-04-10 Janssen Pharmaceutica N.V. GlyT2 modulators
FR2869903B1 (en) * 2004-05-06 2006-06-23 Galderma Res & Dev NOVEL BI-AROMATIC RECEPTOR ACTIVATOR COMPOUNDS OF THE PPARY TYPE, PROCESS FOR THEIR PREPARATION AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS
JP4047365B2 (en) * 2006-01-11 2008-02-13 生化学工業株式会社 Cycloalkanecarboxamide derivative and method for producing the same
EP2040690B1 (en) * 2006-06-28 2014-08-06 Sanofi Inhibitors of cxcr2
US20120004273A1 (en) * 2007-01-20 2012-01-05 Nadia Mamoona Ahmad Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
WO2009034062A1 (en) * 2007-09-11 2009-03-19 Glaxo Group Limited Compounds which inhibit the glycine transporter and uses thereof in medicine
AU2009314299A1 (en) * 2008-11-12 2010-05-20 Merck Sharp & Dohme Corp. Inhibitors of fatty acid binding protein (FABP)

Also Published As

Publication number Publication date
KR101804650B1 (en) 2018-01-10
WO2014146995A1 (en) 2014-09-25
CA2898534C (en) 2017-09-19
BR112015024109A2 (en) 2017-07-18
MX2015013365A (en) 2016-01-08
CN105308020B (en) 2018-01-26
US9278918B2 (en) 2016-03-08
EP2991967A1 (en) 2016-03-09
CN105308020A (en) 2016-02-03
US20160002152A1 (en) 2016-01-07
HK1214238A1 (en) 2016-07-22
RU2642454C2 (en) 2018-01-25
JP2016514106A (en) 2016-05-19
AR095570A1 (en) 2015-10-28
JP6235048B2 (en) 2017-11-22
CA2898534A1 (en) 2014-09-25
KR20150119357A (en) 2015-10-23
TW201514138A (en) 2015-04-16
TWI629258B (en) 2018-07-11

Similar Documents

Publication Publication Date Title
RU2015140599A (en) UREA DERIVATIVES AND THEIR APPLICATION AS PROTEIN INHIBITORS, BINDING FATTY ACIDS
RU2017127135A (en) THERAPEUTICALLY AGAINST CANCER OF CANCER
HRP20180916T1 (en) Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use
JP2016530310A5 (en)
NZ598294A (en) Heterocyclic compounds for the inhibition of pask
IL264982B (en) (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
JP2010524952A5 (en)
EA201490407A1 (en) CONTAINING HYDRAZIDE MODULATORS OF NUCLEAR TRANSPORT AND THEIR APPLICATION
RU2015126015A (en) NEW CATCHERS IN THE TREATMENT OF MACULODYSTROPHY
RU2011108281A (en) TRIPYRIDYL CARBOXAMIDE ANTAGONISTS OF OREXIN RECEPTORS
WO2012122865A3 (en) Pharmaceutically acceptable salt of (e)-n-[4-[[3-chloro-4-(2-pyridylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolyl]-3-[(2r)-1-methylpyrrolidin-2-yl]prop-2-enamide, preparation method therefor, and medical use thereof
UA111569C2 (en) Combination of active ingredients comprising pyridyl ethylbenzamides and other active ingredients
NZ603198A (en) Novel hydroxamic acid derivative
RU2015113746A (en) SUBSTITUTED SULFONAMIDES
RU2016134749A (en) HETEROCYCLIC SULPHONAMIDE DERIVATIVE AND MEDICINE CONTAINING SUCH DERIVATIVE
WO2012113873A3 (en) Organic compounds
WO2012149157A3 (en) Heterocyclic compounds for the inhibition of pask
WO2009109867A3 (en) Crystal form of phenylamino pyrimidine derivative
JP2015524472A5 (en)
JP2018048143A5 (en)
RU2016110096A (en) NEW QUINOLINE-SUBSTITUTED COMPOUND
JP2014534981A5 (en)
RU2017117566A (en) ACTIVATOR KCNQ2-5 CHANNELS
JP2014505107A5 (en)
NZ704799A (en) Heterocyclic modulators of hif activity for treatment of disease